Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bakris

Showing results (531-540 of 738) with videos related to

Pageof 74
Sort By:
Nature Reviews. Disease Primers|March 23, 2018
HypertensionSuzanne Oparil, Maria Czarina Acelajado, George L Bakris, et al.
American Heart Journal|September 24, 2017
High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3Ron Waksman, George L Bakris, Arie Steinvil, et al.
Hypertension (Dallas, Tex. : 1979)|October 17, 2022
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 DiabetesLuis M Ruilope, Rajiv Agarwal, Stefan D Anker, et al.
Blood Pressure|July 7, 2007
Exceptional early blood pressure control rates: the ACCOMPLISH trialKenneth Jamerson, George L Bakris, Björn Dahlöf, et al.
Hypertension (Dallas, Tex. : 1979)|December 30, 2010
Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure controlKenneth A Jamerson, Richard Devereux, George L Bakris, et al.
American Heart Journal|May 16, 2016
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trialYuichi J Shimada, Christopher P Cannon, Yuyin Liu, et al.
The New England Journal of Medicine|July 19, 2023
Zilebesiran, an RNA Interference Therapeutic Agent for HypertensionAkshay S Desai, David J Webb, Jorg Taubel, et al.
Journal of the American Society of Nephrology : JASN|November 4, 2021
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD TrialRajiv Agarwal, Amer Joseph, Stefan D Anker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 21, 2013
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKDSandra J Taler, Rajiv Agarwal, George L Bakris, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 14, 2022
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)Jennifer B Green, Amy K Mottl, George Bakris, et al.
Pageof 74

Showing results (531-540 of 738) with videos related to

Sort By:
Pageof 74
Nature Reviews. Disease Primers|March 23, 2018
HypertensionSuzanne Oparil, Maria Czarina Acelajado, George L Bakris, et al.
American Heart Journal|September 24, 2017
High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3Ron Waksman, George L Bakris, Arie Steinvil, et al.
Hypertension (Dallas, Tex. : 1979)|October 17, 2022
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 DiabetesLuis M Ruilope, Rajiv Agarwal, Stefan D Anker, et al.
Blood Pressure|July 7, 2007
Exceptional early blood pressure control rates: the ACCOMPLISH trialKenneth Jamerson, George L Bakris, Björn Dahlöf, et al.
Hypertension (Dallas, Tex. : 1979)|December 30, 2010
Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure controlKenneth A Jamerson, Richard Devereux, George L Bakris, et al.
American Heart Journal|May 16, 2016
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trialYuichi J Shimada, Christopher P Cannon, Yuyin Liu, et al.
The New England Journal of Medicine|July 19, 2023
Zilebesiran, an RNA Interference Therapeutic Agent for HypertensionAkshay S Desai, David J Webb, Jorg Taubel, et al.
Journal of the American Society of Nephrology : JASN|November 4, 2021
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD TrialRajiv Agarwal, Amer Joseph, Stefan D Anker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 21, 2013
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKDSandra J Taler, Rajiv Agarwal, George L Bakris, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 14, 2022
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)Jennifer B Green, Amy K Mottl, George Bakris, et al.
Pageof 74